Ascendis Pharma A (ASND) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ascendis Pharma A’s revenue went from $5M in fiscal 2016 to $846M in fiscal 2025, growth of about 77.4% a year.
Net income in fiscal 2025 was -$268M, a net margin of -31.7%; the best year in this period was 2016 with -$72M.
Over the twelve months to September 30, 2026, revenue was $1.3B and net income $966M.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $846M | $378M | $295M | $55M | $9M | $9M | $15M | $12M | $2M | $5M |
| Gross profit | — | $735M | $332M | $246M | $42M | $5M | $9M | $15M | — | — | — |
| Operating income | — | -$160M | -$290M | -$503M | -$599M | -$512M | -$406M | -$255M | -$177M | -$134M | -$77M |
| Net income | $966M | -$268M | -$393M | -$532M | -$622M | -$434M | -$514M | -$245M | -$149M | -$149M | -$72M |
| EPS (diluted) | $14.78 | $-4.07 | $-5.96 | $-8.07 | $-9.44 | $-6.59 | $-7.80 | $-3.72 | $-2.26 | $-2.26 | $-1.10 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +124.0% | +28.2% | +440.0% | +519.6% | +3.2% | −43.2% | +24.0% | +560.3% | −62.2% | −45.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $591M | $63M | -$318M | -$516M | -$529M | -$473M | -$333M | -$198M | -$159M | -$114M | -$63M |
| Capital spending | -$19M | — | — | -$3M | -$15M | -$27M | -$24M | -$6M | -$3M | -$1M | -$708353 |
| Free cash flow | $572M | — | — | -$519M | -$544M | -$500M | -$358M | -$203M | -$162M | -$115M | -$64M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | $20M | $0 | $0 | $112M | $24M | — | — | — | — | — |
| Stock-based pay | — | $137M | $99M | $74M | $68M | $76M | $65M | $42M | $23M | $12M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $724M | $581M | $433M | $474M | $505M | $717M | $672M | $318M | $234M | $190M |
| Debt | — | $957M | $855M | $696M | $426M | $119M | — | — | — | — | — |
| Equity | — | -$191M | -$110M | -$161M | $281M | $1.0B | $1.0B | $671M | $321M | $225M | $186M |
| Total assets | — | $1.5B | $1.2B | $912M | $1.2B | $1.2B | $1.2B | $760M | $365M | $253M | $200M |
| Shares (diluted) | 65M | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M | 66M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 86.8% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | — | — | — |
| Operating margin | — | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | -1583.2% |
| Net margin | 72.9% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% |
| FCF margin | 43.1% | — | — | -176.1% | -997.0% | -5674.4% | -4191.1% | -1354.0% | -1336.8% | -6277.1% | -1321.1% |
| ROIC | — | -16.5% | -30.7% | -74.3% | -67.0% | -45.7% | -39.4% | -37.9% | -55.1% | -59.4% | -41.1% |
| ROE | — | 140.1% | 357.7% | 330.4% | -221.5% | -43.4% | -50.0% | -36.5% | -46.5% | -66.2% | -38.8% |
Frequently asked questions
What is Ascendis Pharma A’s annual revenue?
$846M in fiscal 2025 and $1.3B over the twelve months to September 30, 2026.
How much profit does Ascendis Pharma A make?
Net income was -$268M in fiscal 2025 (net margin -31.7%).
Is Ascendis Pharma A’s revenue growing?
Yes: revenue rose 124.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.